npj Breast Cancer (Sep 2023)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer

  • Nicola Cosgrove,
  • Alex J. Eustace,
  • Peter O’Donovan,
  • Stephen F. Madden,
  • Bruce Moran,
  • John Crown,
  • Brian Moulton,
  • Patrick G. Morris,
  • Liam Grogan,
  • Oscar Breathnach,
  • Colm Power,
  • Michael Allen,
  • Janice M. Walshe,
  • Arnold D. Hill,
  • Anna Blümel,
  • Darren O’Connor,
  • Sudipto Das,
  • Małgorzata Milewska,
  • Joanna Fay,
  • Elaine Kay,
  • Sinead Toomey,
  • Bryan T. Hennessy,
  • Simon J. Furney

DOI
https://doi.org/10.1038/s41523-023-00572-9
Journal volume & issue
Vol. 9, no. 1
pp. 1 – 16

Abstract

Read online

Abstract HER2-positive (HER2+) breast cancer accounts for 20–25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10–05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using clinicopathological and genomic features of pre-treatment tumour biopsies identified age, estrogen receptor (ER) status and level of immune cell infiltration may together be important for predicting response. Clonal evolution analysis of longitudinally collected tumour samples show subclonal diversity and dynamics are evident with potential therapy resistant subclones detected. The sources of greater pre-treatment immunogenicity associated with a pathological complete response is largely unexplored in HER2+ tumours. However, here we point to the possibility of APOBEC associated mutagenesis, specifically in the ER-neg/HER2+ subtype as a potential mediator of this immunogenic phenotype.